<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<html>
<head>
<title>L. Stratchounski, I. Edelstein, A. Narezkina, M. Edelstein, M. Pimkin - In vitro activity of cefoperazone/sulbactam vs amoxicillin/clavulanic acid and piperacillin/tazobactam against extended spectrum b-lactamase (ESBL)-producing strains of Escherichia coli and Klebsiella pneumoniae</title>
<meta name="description" content="In vitro activity of cefoperazone/sulbactam vs amoxicillin/clavulanic acid and piperacillin/tazobactam against extended spectrum b-lactamase (ESBL)-producing strains of Escherichia coli and Klebsiella pneumoniae">
<meta name="keywords" content="In vitro, activity, cefoperazone/sulbactam, amoxicillin/clavulanic acid,  piperacillin/tazobactam, b-lactamase, ESBL-producing,  Escherichia coli, Klebsiella pneumoniae, L. Stratchounski, I. Edelstein, A. Narezkina, M. Edelstein, M. Pimkin">
<script language="JavaScript1.2"> <!--//
function btn(ind,picture) {document.images[ind].src=picture;}
//--> </script>

<script language="JavaScript"> <!--// 
document.write('<link rel="StyleSheet" type="text/css" href="/en/inc/');
if (navigator.appName=="Netscape") {
	document.write("nn")
} else {
	document.write("ie")
}
document.write('.css">');
//-->
</script>
<noscript><link rel="StyleSheet" type="text/css" href="../../inc/ie.css"></noscript>

<style type="text/css">
P {margin-top: 10px; margin-left: 10px; text-align: justify;}
LI {margin-top: 8px; margin-left: 15px; text-align: justify;}
H4 {margin-left: 10px;}
H5 {font-size: 11pt}
H5.l {text-align: left;}
</style>
</head>

<body class="main">

<table width="750" cellpadding="0" border="0" cellspacing="5">
<tr>
  <th width="150" valign="top">

  <table border="0" cellpadding="5" cellspacing="0" width="100%">
    <tr><td>
<p class="m10"><b>Antimicrobial Resistance</b></p>
<hr size="1" style="color: #D0C0AC;">
<p class="m8"><a href="../index.shtml#rus">Antimicrobial Resistance in Russia</a></p>
<p class="m8"><a href="../index.shtml#pub">Publications</a></p>
<p class="m8"><a href="../links.shtml">References</a></p>

    </td></tr>
  </table>
  

  </th><td valign="top">
<!--navigation-->
<map name="TopBtnEn">
<area shape="circle" coords="15,15,15" href="javascript:history.go(-1)" alt="Previous page" title="Previous page">
<area shape="circle" coords="46,15,15" href="javascript:history.go(+1)" alt="Next page" title="Next page">
<area shape="circle" coords="77,15,15" href="../../index-1.htm" alt="Main page" title="Main page">
<area shape="circle" coords="108,15,15" href="mailto:website@antibiotic.ru" alt="E-Mail" title="E-Mail">
</map>
<table border="0" cellpadding="0" cellspacing="0" width="100%"> <!--1-->
<tr>
  <td bgcolor="#F8F3E6" background="/rus/images/buttons/topline.gif" style="background-color: #F8F3E6; background-image: url(../../../rus/images/buttons/topline.gif);" width="98%" height="32"><img src="../../../rus/images/inv.gif" width="1" height="32" border="0" alt=""></td>
  <td width="1%"><font size="1"><img src="../../../rus/images/buttons/topbtn.gif" width="126" height="32" border="0" alt="Navigation" usemap="#TopBtnEn"></font></td>
</tr>
</table>
<!--/navigation-->

<h2><a name="top"></a>12<sup>th</sup> European Congress of Clinical Microbiology and Infectious Diseases</h2>
<h5><i>24â€“27 April, Italy, Milan</i></h5>
<h5><b>Poster # P1413</b></h5>

<h1><i>In vitro</i> activity of cefoperazone/sulbactam vs amoxicillin/clavulanic acid and piperacillin/tazobactam against extended spectrum <font face="Symbol">b</font>-lactamase (ESBL)-producing strains of <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i></h1>

<h5><i>L.&nbsp;Stratchounski, I.&nbsp;Edelstein, A.&nbsp;Narezkina, M.&nbsp;Edelstein, M.&nbsp;Pimkin</i></h5>

<h5 style="font-size:10pt; text-align:left; margin-left:10px;"><i>Institute of Antimicrobial Chemotherapy, Smolensk</i></h5>

<p style="text-align:right; font-size:8pt"><a target="_blank" href="../../pdfs/p1413.pdf">The PDF format poster (156 kb) <img src="../../images/pdf.gif" width="16" height="16" alt="" border="0"></a></p>

<hr size="1">

<ul>
  <li><a href="#1">Abstract</a></li>
  <li><a href="#2">Introduction and purpose</a></li>
  <li><a href="#3">Methods</a></li>
  <li><a href="#4">Results and discussion</a></li>
  <li><a href="#5">Conclusions</a></li>
</ul>
<hr size="1">

<a name="1"></a><br>
<h2>ABSTRACT</h2>

<p><b>Objective:</b> To compare <i>in vitro</i> activity of the most commonly used penicillin-inhibitor combinations (amoxicillin/clavulanic acid (AMC), piperacillin/tazobactam (PTZ)) and cefoperazone/sulbactam (CPS) against nosocomial extended-spectrum <font face="Symbol">b</font>-lactamases (ESBL)-producing <i>E.coli</i> and <i>K.pneumoniae</i>.</p>

<p><b>Methods:</b> A total of 209 ESBL-producing <i>E.coli</i> (n=49) and <i>K.pneumoniae</i> (n=160) collected in 21 Russian hospitals during 1997-1998 were included in this study. The presence of an ESBL was detected by Etest ESBL strips. Susceptibility to AMC (2/1), PTZ (4&nbsp;mg/L - fixed tazobactam concentration) and CPS (1/1) was determined using Etest and results were interpreted according to the current NCCLS guidelines. The susceptibility to CPS was determined on the basis of cefoperazone MIC breakpoints.</p>

<p><b>Results:</b> The results of susceptibility testing are summarised in the <a href="#t1">Table&nbsp;1</a>. The penicillin-inhibitor combinations were not active <i>in vitro</i> against a significant proportion of ESBL-producers and the MIC<sub>90</sub> values of both AMC and PTZ exceeded the resistance levels advocated by NCCLS. At the same time, CPS was active against the majority of strains with the exception of single <i>K.pneumoniae</i> isolate (0.5%) expressing a high level of resistance (MIC 96&nbsp;mg/L) and 12 (5.7%) intermediately resistant strains.</p>

<p><b>Conclusion:</b> Among all <font face="Symbol">b</font>-lactam-inhibitor combinations tested CPS revealed the highest activity against ESBL-producing organisms. Its superior activity is probably attributed to the improved stability of cefoperazone and to the high concentration of the inhibitor component (sulbactam).</p>

<a name="2"></a><br>
<h2>INTRODUCTION AND PURPOSE</h2>

<p>Resistance of nosocomial <i>Enterobacteriaceae</i> to modern <font face="Symbol">b</font>-lactams mediated by production of ESBLs has emerged as important public health problem worldwide. Our previous studies have demonstrated the alarmingly high rates (up to 90%) of ESBL production among <i>E.coli</i> and <i>K.pneumoniae</i> strains isolated in acute and intensive care units of many Russian hospitals.</p>

<p>The concomitant decrease in efficiency of extended-spectrum cephalosporins emphasize the necessity of selection of an appropriate empiric treatment of nosocomial infections caused by ESBL-producing pathogens. <font face="Symbol">b</font>-Lactam-<font face="Symbol">b</font>-lactamase inhibitor combinations may be considered as potential alternative to III and IV generation cephalosporins, because ESBLs are usually susceptible to inhibitors (clavulanic acid, tazobactam, sulbactam). In practice, however, various <font face="Symbol">b</font>-lactam-inhibitor combinations differ significantly in their activity against ESBL-producing strains. Resistance to inhibitor-protected penicillins (ampicillin/sulbactam, amoxicillin/clavulanic acid, ticarcillin/clavulanic acid and piperacillin/tazobactam) is often achieved by either the overproduction of ESBL or the production of ESBL in combination with penicillinases (TEM&nbsp;1 or SHV&nbsp;1). Cefoperazone/sulbactam (1:1) is a unique combination of III generation cephalosporin that is more stable to <font face="Symbol">b</font>-lactamases then penicillins with inhibitor at the highest available ratio. Nevertheless, the data comparing the activity of cefoperazone/sulbactam and penicillin-inhibitor combinations against the large number of clinical ESBL-producing strains are still lacking. The aim of our study was to determine the relative efficiency of amoxicillin/clavulanic acid, piperacillin/tazobactam and cefoperazone/sulbactam against ESBL-producing <i>E.coli</i> and <i>K.pneumoniae</i> strains isolated in Russian hospitals.</p>

<a name="3"></a><br>
<h2>METHODS</h2>

<p><b>Bacterial isolates.</b> A total of 209 <i>E.coli</i> (n=49) and <i>K.pneumoniae</i> (n=160) strains producing ESBLs were collected in 21 hospitals from geographical distinct regions of Russia during 1997-1998. All strains were reidentified in the laboratory of the Institute of Antimicrobial Chemotherapy using API20E system (bioMerieux, France) and stored at -70<sup>o</sup>C until analysis.</p>

<p><b>ESBL detection.</b> The presence of ESBL was confirmed using Etest strips containing ceftazidime (TZ) and ceftazidime/clavulanic acid (TZL) as recommended by manufacturer (AB Biodisk, Sweden). The MIC ratio of TZ/TZL 8 was used as a strict criterion of ESBL production. The strains producing the known ESBLs: <i>E.coli</i> DH5<font face="Symbol">a</font> (TEM-12), <i>E.coli</i> J53 (SHV-2) and <i>E.coli</i> AB1456 (CTX-M-4) were used as quality controls for this procedure.</p>

<p><b>Susceptibility testing.</b> MICs of amoxicillin/clavulanic acid (AMC, 2/1), piperacillin/tazobactam (PTZ, 4&nbsp;mg/L - fixed tazobactam concentration) and cefoperazone/sulbactam (CPS, 1/1) were determined using Etests on Mueller-Hinton agar (BBL, USA) inoculated with bacterial suspensions equivalent to 0.5 MacFarland turbidity standard. The susceptibilities were recorded after 24h incubation at 35<sup>o</sup>C and interpreted according to the current NCCLS guidelines. The cefoperazone breakpoints were used to assign S-I-R categories for cefoperazone/sulbactam, since no criteria are currently provided by NCCLS for interpreting susceptibility to this drug combination. <i>E.coli</i> ATCC<sup>&reg;</sup>25922 and <i>E.coli</i> ATCC<sup>&reg;</sup>35218 strains were used for quality control of susceptibility testing. The term nonsusceptible was used for resistant and intermediately resistant strains.</p>

<a name="4"></a><br>
<h2>RESULTS AND DISCUSSION</h2>

<p><a href="#f1">Figure&nbsp;1</a> shows the frequency distribution of MICs of AMC, PTZ and CPS in ESBL-producing <i>E.coli</i> and <i>K.pneumoniae</i> isolates. As it may be seen from the shape of the MIC distribution graphs, the assignment of susceptibility categories on the basis of fixed MIC breakpoints advocated by NCCLS may be subjective for the group of tested isolates. Nevertheless, the necessity in extensively validated and internationally accepted  criteria for comparing the susceptibility data prevented us from the use of any alternative definitions of resistance categories. Based on the NCCLS interpretive criteria,  131 (81,9%) and 77 (48,1%) ESBL-producing isolates were nonsusceptible to AMC and PTZ, respectively (<a href="#t1">Table&nbsp;1</a>). It is important to emphasize that 88 (55%) and 54 (33,8%) of isolates expressed high-level resistance to these antimicrobial combinations. Moreover, the MIC<sub>90</sub> values of both AMC and PTZ exceeded the resistance levels advocated by NCCLS.</p>

<a name="t1"></a><br>
<p class="l"><b>Table 1.</b> Percentage of nonsusceptible ESBL-producing isolates and MIC<sub>50</sub>, MIC<sub>90</sub> values (mg/L) of amoxicillin/clavulanic acid (AMC), piperacillin/tazobactam (PTZ) and cefoperazone/sulbactam (CPS).</p>

<table border="0" cellpadding="0" cellspacing="10" width="100%"><tr><td bgcolor="#CC9988">
<table width="100%" cellpadding="5" cellspacing="1" border="0">
<tr>
	<th width="19%" rowspan="2">&nbsp;</th>
	<th width="27%" colspan="3">AMC</th>
	<th width="27%" colspan="3">PTZ</th>
	<th width="27%" colspan="3">CPS</th>
</tr>
<tr>
	<th width="9%">%I+R</th>
	<th width="9%">MIC<sub>50</sub></th>
	<th width="9%">MIC<sub>90</sub></th>
	<th width="9%">%I+R</th>
	<th width="9%">MIC<sub>50</sub></th>
	<th width="9%">MIC<sub>90</sub></th>
	<th width="9%">%I+R</th>
	<th width="9%">MIC<sub>50</sub></th>
	<th width="9%">MIC<sub>90</sub></th>
</tr>
<tr>
	<td class="cl"><i>E.coli</i></td>
	<td class="cc">85.7</td>
	<td class="cc">24</td>
	<td class="cc">48</td>
	<td class="cc">36.7</td>
	<td class="cc">4</td>
	<td class="cc">256</td>
	<td class="cc">2.0</td>
	<td class="cc">4</td>
	<td class="cc">12</td>
</tr>
<tr>
	<td class="cl"><i>K.pneumoniae</i></td>
	<td class="cc">81.9</td>
	<td class="cc">32</td>
	<td class="cc">64</td>
	<td class="cc">48.1</td>
	<td class="cc">16</td>
	<td class="cc">256</td>
	<td class="cc">6.9</td>
	<td class="cc">6</td>
	<td class="cc">16</td>
</tr>
<tr>
	<td class="cl">Both species</td>
	<td class="cc">82.8</td>
	<td class="cc">32</td>
	<td class="cc">64</td>
	<td class="cc">45.5</td>
	<td class="cc">12</td>
	<td class="cc">256</td>
	<td class="cc">5.7</td>
	<td class="cc">6</td>
	<td class="cc">16</td>
</tr>
</table>
</td></tr></table>

<a name="f1"></a><br>
<div align="center"><font size="1"><img src="images/p1413r1amc.gif" width="380" height="275" alt="" border="0"><br>
<img src="images/p1413r1ptz.gif" width="380" height="276" alt="" border="0"><br>
<img src="images/p1413r1cps.gif" width="380" height="270" alt="" border="0"></font></div>

<p class="l"><b>Figure 1.</b> Frequency distribution of MICs of AMC, PTZ and CPS in <i>E.coli</i> and <i>K.pneumoniae</i> ESBL-producing isolates.</p><br>

<p>In contrast with penicillin-inhibitor combinations, CPS was active against the majority of strains with the exception of single  <i>K.pneumoniae</i> isolate (0.5%) expressing a high level of resistance (MIC 96&nbsp;mg/L) and 12 (5.7%) intermediately resistant strains. Eleven of those intermediately resistant strains were <i>K.pneumoniae</i> having the CPS MICs of 24-32&nbsp;mg/L. A single <i>E.coli</i> strain had the CPS MIC of 32&nbsp;mg/L.</p>

<p>Although there were more <i>K.pneumoniae</i> than <i>E.coli</i> nonsusceptible strains, the MIC<sub>50</sub> and MIC<sub>90</sub> values of CPS did not differ significantly between the species and were below the resistance level for both <i>E.coli</i> and <i>K.pneumoniae</i>.</p>

<p>The low activity of AMC and PTZ against the isolates included in this survey is more likely explained by high rates of co-production of ESBL and plasmid-mediated penicillinases of TEM-, SHV- or OXA-types described in many publications. Furthermore, the presence of chromosomally encoded SHV-1 <font face="Symbol">b</font>-lactamase is typical for all <i>K.pneumoniae</i> isolates (D.&nbsp;Livermore, 2001). The isolates co-producing ESBL and penicillinase at high levels are likely to develop resistance to penicilline-inhibitor combinations, since the concentration of inhibitor component in their periplasmic space may be insufficient to protect a penicillin. On the other hand, both the relatively high stability of cefoperazone and the increased concentration of sulbactam lead to the greater activity of their combination against ESBL producers. <a href="#f2">Figure&nbsp;2</a> shows an example of the influence of supplementary penicillinases (TEM-1 and SHV-1) on the activity of different <font face="Symbol">b</font>-lactam-inhibitor combinations against the strains producing the same type of ESBL (SHV-2).</p>

<a name="f2"></a><br>
<div align="center"><font size="1"><img src="images/p1413r2a.jpg" width="414" height="250" alt="The influence of supplementary penicillinases on the activity of different b-lactam-inhibitor combinations against strains producing the same type of ESBL" border="0"></font></div>
<p class="c"><i>E.coli</i> J53<br>(SHV-2)<br>MIC<sub>AMC</sub>	12 mg/L<br>MIC<sub>PTZ</sub>	1,5 mg/L<br> MIC<sub>CPS</sub>1 mg/L</p><br>

<div align="center"><font size="1"><img src="images/p1413r2b.jpg" width="396" height="254" alt="The influence of supplementary penicillinases on the activity of different b-lactam-inhibitor combinations against strains producing the same type of ESBL" border="0"></font></div>
<p class="c"><i>K.pneumoniae</i> 16SRH - clinical isolate<br>(SHV-2 + SHV-1 + TEM-1)<br>
MIC<sub>AMC</sub> 48 mg/L<br>MIC<sub>PTZ</sub> 64 mg/L<br>MIC<sub>CPS</sub> 4 mg/L</p>

<p class="l"><b>Figure 2.</b> The influence of supplementary penicillinases on the activity of different <font face="Symbol">b</font>-lactam-inhibitor combinations against strains producing the same type of ESBL.</p><br>

<a name="5"></a><br>
<h2>CONCLUSIONS</h2>

<ul>
  <li>Among all <font face="Symbol">b</font>-lactam-inhibitor combinations tested cefoperazone/sulbactam  (1:1) revealed the highest activity against ESBL-producing <i>E.coli</i> and <i>K.pneumoniae</i> and may be used for empirical therapy of nosocomial infections caused by this type of organisms.</li>
  <li>The penicillin-inhibitor combinations were not effective against a significant proportion of studied isolates and therefore their usefulness in the treatment of infections due to ESBL producers is doubtful.</li>
</ul>

<br>
<!-- begin footer -->
<table border="0" cellpadding="5" cellspacing="0" width="100%">
<tr>
  <td style="text-align: left; vertical-align: bottom;" align="left" valign="bottom"><div class="t8">&copy; 2000-2006 IAC SSMA &middot; E-mail: <a href="mailto:website@antibiotic.ru" title="Send e-mail">website&#64;antibiotic&#46;ru</a></div></td>
  <td colspan="2" valign="top" align="right"><font size="1"><!-- SpyLOG v2 f:0211 --><script language="javascript">
u="u607.38.spylog.com";d=document;nv=navigator;na=nv.appName;p=1;
bv=Math.round(parseFloat(nv.appVersion)*100);
n=(na.substring(0,2)=="Mi")?0:1;rn=Math.random();z="p="+p+"&rn="+rn;y="";
y+="<a href='http://"+u+"/cnt?f=3&p="+p+"&rn="+rn+"' target=_blank>";
y+="<img src='http://"+u+"/cnt?"+z+
"&r="+escape(d.referrer)+"&pg="+escape(window.location.href)+"' border=0  width=88 height=31  alt='SpyLOG'>";
y+="</a>"; d.write(y);if(!n) { d.write("<"+"!--"); }//--></script><noscript>
<a href="../../../index-15.htm?f=3&p=1" target="_blank">
<img src="../../../digits.png?p=1" alt='SpyLOG' border='0' width="88" height="31">
</a></noscript><script language="javascript1.2"><!--
if(!n) { d.write("--"+">"); }//--></script><!-- SpyLOG  --></font></td>
</tr>
</table>
<!-- end of footer -->

  </td></tr>
</table>
</body>
</html>
